LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Plasma Metabolite Profile and Gut Microbiota Connected to Obesity

By LabMedica International staff writers
Posted on 14 Mar 2018
Print article
Image: Liquid chromatography-mass spectrometry used for targeted profiling of plasma metabolites (Photo courtesy of McGill University).
Image: Liquid chromatography-mass spectrometry used for targeted profiling of plasma metabolites (Photo courtesy of McGill University).
A new link has been discovered between gut bacteria and obesity. It has been found that certain amino acids in the blood can be connected to both obesity and the composition of the gut microbiome.

Emerging evidence has related the gut microbiome and circulating metabolites to human obesity. Gut microbiota is responsible for several metabolic functions and altered plasma metabolome may reflect differences in the gut microbiome.

Scientists at Lund University (Malmö, Sweden) analyzed blood plasma and stool samples from participants in the Malmö Offspring Study (MOS). Targeted profiling of 48 plasma metabolites was performed in a population of 920 Swedish adults (mean age 39 years, 53% were women) using targeted liquid chromatography-mass spectrometry. Gut microbiota was analyzed by sequencing of the16S rRNA gene (V1-V3 region) in fecal samples of 674 study participants.

The scientists reported that body mass index (BMI) was associated with 19 metabolites, of which glutamate provided the strongest direct association. By orthogonal partial least squares regression a metabolite principal component predictive of BMI was constructed (PCBMI). In addition to glutamate, PCBMI was dominated by branched chain amino acids (BCAA) and related metabolites. Four gut microbiota genera in the Lachnospiraceae family: L. blautia, L. dorea, L. ruminococcus and SHA-98) were associated with both BMI and PCBMI . When simultaneously regressing the PCBMI and the metabolite associated gut bacteria against BMI, only PCBMI remained significant.

Marju Orho-Melander, PhD, a professor of genetic epidemiology and senior investigator of the study, said, “The differences in BMI were largely explained by the differences in the levels of glutamate and BCAA. This indicates that the metabolites and gut bacteria interact, rather than being independent of each other. This means that future studies should focus more on how the composition of gut bacteria can be modified to reduce the risk of obesity and associated metabolic diseases and cardiovascular disease.” The study was published on February 1, 2018, in The Journal of Clinical Endocrinology & Metabolism.

Related Links:
Lund University

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.